Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Luong Ly

Infectious Disease Pasadena, CA Medical Doctor

NPI 1538101670 CMS profile 342128

99 S Raymond Ave # 610, Pasadena, CA 91105

Open in the dashboard

General payments

$53,984

112 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Luong Ly of Pasadena, CA is reported in the CMS Open Payments database as having received $53,984 across 112 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $171 2
2023 General $2,373 4
2022 General $2,472 9
2021 General $1,770 13
2020 General $13,570 27
2019 General $33,628 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luong Ly
  • Infectious Disease median
  • Middle half of Infectious Disease
  • National median

In program year 2025, general payments to Luong Ly were reported at $0. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.

Show as a table
Year Luong Ly Infectious Disease median Middle half National median
2019 $33,628 $190 $60–$862 $163
2020 $13,570 $124 $32–$606 $114
2021 $1,770 $148 $38–$905 $132
2022 $2,472 $166 $50–$834 $149
2023 $2,373 $171 $57–$787 $160
2024 $171 $176 $52–$752 $164
2025 $0 $188 $57–$766 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Merck Sharp & Dohme Corporation $26,949 44 payments
  2. Allergan Inc. $20,121 36 payments
  3. Tetraphase Pharmaceuticals, Inc. $4,789 9 payments
  4. AbbVie, Inc. $2,091 22 payments
  5. Radius Health, Inc. $35 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $43,530 27 payments
  2. Honoraria $4,417 3 payments
  3. Food and Beverage $4,071 60 payments
  4. Travel and Lodging $1,958 20 payments
  5. Gift $9 2 payments
Products named General payments · program years 2019–2024
  1. ZERBAXA $17,560 27 payments
  2. DALVANCE $13,972 27 payments
  3. AVYCAZ $8,070 31 payments
  4. RECARBRIO $4,696 6 payments
  5. Xerava Complicated Intra-Abdominal Infections $3,107 6 payments
  6. ZINPLAVA $1,970 3 payments
  7. XERAVA Tetracycline Class Antibacterial $1,681 3 payments
  8. TEFLARO $231 2 payments
  9. Tymlos $35 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

112 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Infectious Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record